tapinarof cream, 1%

DRUG9 trials

Sponsors

Organon and Co, Sun Pharmaceutical Industries, Inc.

Conditions

Atopic DermatitisPlaque Psoriasis

Phase 1

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

CompletedNCT07546214

Sun Pharmaceutical Industries, Inc.Plaque Psoriasis

Start: 2025-10-13End: 2026-03-18Updated: 2026-04-22

Phase 2

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

CompletedNCT04042103

Organon and CoPlaque Psoriasis

Start: 2019-07-23End: 2020-01-09Updated: 2025-06-19

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

CompletedNCT05186805

Organon and CoAtopic Dermatitis

Start: 2021-11-15End: 2022-08-24Updated: 2025-09-05

Phase 3

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

CompletedNCT04053387

Organon and CoPlaque Psoriasis

Start: 2019-08-13End: 2021-04-06Updated: 2025-08-06

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

CompletedNCT05014568

Organon and CoAtopic Dermatitis

Start: 2021-09-01End: 2023-04-07Updated: 2025-09-04

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

CompletedNCT05032859

Organon and CoAtopic Dermatitis

Start: 2021-09-23End: 2023-02-08Updated: 2025-09-02

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

CompletedNCT05142774

Organon and CoAtopic Dermatitis

Start: 2021-10-28End: 2024-03-07Updated: 2025-08-13

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Active, not recruitingNCT05172726

Organon and CoPlaque Psoriasis

Start: 2021-12-02End: 2026-10-01Updated: 2026-04-17

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Active, not recruitingNCT07265479

Organon and CoAtopic Dermatitis

Start: 2025-12-29End: 2027-08-01Updated: 2026-08-12

Related Papers

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

2025-07-221 citations

Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.

2025-07-02

Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.

2025-03-242 citations

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Journal of Dermatological Treatment2025-01-125 citations

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.

2025-01-074 citations

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis

Dermatology and Therapy2023-12-216 citations

Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.

2023-12-012 citations

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials

Dermatology and Therapy2023-09-118 citations

301 Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal use trial

British Journal of Dermatology2023-01-251 citations

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.

2021-10-2827 citations